BioSpace News Archive

Based on publicly available data, a data model on a recently launched website set up by an ad-hoc group of scientists predicts the number of new, confirmed novel coronavirus cases in China to dwindle to almost nothing in under two weeks.

Further to my statement on February 9, 2020, as Chief Public Health Officer, I have assessed additional individuals in quarantine at Canadian Forces Base Trenton pursuant to an Emergency Order under the Quarantine Act and determined that they do not pose a risk of significant harm to public health.

International Isotopes Inc. (OTCQB: INIS) (the “Company”) is pleased to announce it has received approval from the U.S. Food and Drug Administration (FDA) for its SODIUM IODIDE I-131 pharmaceutical product. SODIUM IODIDE I-131 is a radioactive therapeutic agent indicated for the treatment of hyperthyroidism and carcinoma of t

Health Canada is advising Canadians that the following products may pose serious health risks.

HITRUST CSF Certification validates Catapult Health is committed to meeting key regulations and protecting sensitive information

Invacare Corporation announced its financial results for the fourth quarter and year ended December 31, 2019.

Edgewell Personal Care Company (NYSE: EPC) today announced results for its first fiscal quarter ending December 31, 2019.

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced that management will present a company overview at the SVB Leerink 9th Annual Global Healthcare Conference on Thursday, February 27, 2020 at 10:00 AM ET in New York, New York.

Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that, as anticipated, the U.S. Food and Drug Administration (FDA) accepted the Company’s New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film for the management of seizure clusters.

Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for IV oliceridine, the Company’s lead investigational product for the management of moderate-to-severe acute pain